{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:25:46Z","timestamp":1790893546066,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11523-020-00702-4","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T15:04:47Z","timestamp":1581692687000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Todd M.","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdi K.","family":"Pithavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Abbattista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson","family":"Peltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"2","key":"702_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34(2):123\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.62.0138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"702_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.lungcan.2013.02.004","volume":"80","author":"LA Berger","year":"2013","unstructured":"Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 2013;80(3):242\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2013.02.004.","journal-title":"Lung Cancer"},{"issue":"4","key":"702_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","volume":"18","author":"A Guerin","year":"2015","unstructured":"Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015;18(4):312\u201322. https:\/\/doi.org\/10.3111\/13696998.2014.1003644.","journal-title":"J Med Econ"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.lungcan.2016.04.006","volume":"97","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Lung Cancer. 2016;97:43\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.006.","journal-title":"Lung Cancer"},{"issue":"23","key":"702_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1408440.","journal-title":"N Engl J Med"},{"issue":"22","key":"702_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.71.5904.","journal-title":"J Clin Oncol"},{"issue":"9","key":"702_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"10072","key":"702_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(17)30123-X.","journal-title":"Lancet"},{"issue":"17","key":"702_CR9","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","volume":"33","author":"DB Costa","year":"2015","unstructured":"Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.59.0539.","journal-title":"J Clin Oncol"},{"issue":"120","key":"702_CR10","doi-asserted-by":"publisher","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117. https:\/\/doi.org\/10.1126\/scitranslmed.3003316.","journal-title":"Sci Transl Med"},{"issue":"24","key":"702_CR11","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","volume":"34","author":"BJ Solomon","year":"2016","unstructured":"Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34(24):2858\u201365. https:\/\/doi.org\/10.1200\/JCO.2015.63.5888.","journal-title":"J Clin Oncol"},{"issue":"15","key":"702_CR12","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","volume":"29","author":"DB Costa","year":"2011","unstructured":"Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443\u20135. https:\/\/doi.org\/10.1200\/JCO.2010.34.1313.","journal-title":"J Clin Oncol"},{"issue":"11","key":"702_CR13","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720\u201344. https:\/\/doi.org\/10.1021\/jm500261q.","journal-title":"J Med Chem"},{"key":"702_CR14","doi-asserted-by":"publisher","first-page":"153601211773666","DOI":"10.1177\/1536012117736669","volume":"16","author":"TL Collier","year":"2017","unstructured":"Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH, et al. Brain penetration of the ROS1\/ALK inhibitor lorlatinib confirmed by PET. Mol Imaging. 2017;16:1536012117736669. https:\/\/doi.org\/10.1177\/1536012117736669.","journal-title":"Mol Imaging"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"15761","DOI":"10.1038\/ncomms15761","volume":"8","author":"TL Collier","year":"2017","unstructured":"Collier TL, Normandin MD, Stephenson NA, Livni E, Liang SH, Wooten DW, et al. Synthesis and preliminary PET imaging of (11)C and (18)F isotopologues of the ROS1\/ALK inhibitor lorlatinib. Nat Commun. 2017;8:15761. https:\/\/doi.org\/10.1038\/ncomms15761.","journal-title":"Nat Commun"},{"issue":"1","key":"702_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70\u201381. https:\/\/doi.org\/10.1016\/j.ccell.2015.05.010.","journal-title":"Cancer Cell"},{"issue":"12","key":"702_CR17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(17)30680-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"702_CR18","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1.","journal-title":"Lancet Oncol"},{"issue":"21","key":"702_CR19","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1810171.","journal-title":"N Engl J Med"},{"issue":"1","key":"702_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/bjc.2017.395","volume":"118","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AC, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018;118(1):38\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.395.","journal-title":"Br J Cancer"},{"issue":"1","key":"702_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"R Soffietti","year":"2013","unstructured":"Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65\u201372. https:\/\/doi.org\/10.1200\/JCO.2011.41.0639.","journal-title":"J Clin Oncol"},{"issue":"4","key":"702_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401\u20139. https:\/\/doi.org\/10.1001\/jama.2016.9839.","journal-title":"JAMA"},{"issue":"6","key":"702_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1256.","journal-title":"Cancer Discov"},{"issue":"2","key":"702_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10585-015-9761-y","volume":"33","author":"M Alsaggar","year":"2016","unstructured":"Alsaggar M, Yao Q, Cai H, Liu D. Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Metastasis. 2016;33(2):115\u201324. https:\/\/doi.org\/10.1007\/s10585-015-9761-y.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"702_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mt.2013.219","volume":"22","author":"C Devaud","year":"2014","unstructured":"Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther. 2014;22(1):18\u201327. https:\/\/doi.org\/10.1038\/mt.2013.219.","journal-title":"Mol Ther"},{"issue":"4","key":"702_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/157339411797642597","volume":"7","author":"T Leal","year":"2011","unstructured":"Leal T, Chang JE, Mehta M, Robins HI. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7(4):319\u201327. https:\/\/doi.org\/10.2174\/157339411797642597.","journal-title":"Curr Cancer Ther Rev"},{"issue":"8","key":"702_CR27","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1097\/JTO.0000000000000174","volume":"9","author":"J Arrondeau","year":"2014","unstructured":"Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Throac Oncol. 2014;9(8):e62\u20133. https:\/\/doi.org\/10.1097\/JTO.0000000000000174.","journal-title":"J Throac Oncol"},{"issue":"2","key":"702_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1634\/theoncologist.2014-0309","volume":"20","author":"SH Ou","year":"2015","unstructured":"Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (>\u200915\u00a0months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015;20(2):224\u20136. https:\/\/doi.org\/10.1634\/theoncologist.2014-0309.","journal-title":"Oncologist"},{"issue":"8","key":"702_CR29","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103\u201310. https:\/\/doi.org\/10.1634\/theoncologist.2018-0380.","journal-title":"Oncologist"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00702-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:01:58Z","timestamp":1628611318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00702-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00702-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"14 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TMB has received fees for consulting\/advisory board roles for Guardant Health, Ignyta, Loxo, Moderna Therapeutics, and Pfizer Inc. ATS has received fees for consulting\/advisory board roles from Ariad\/Takeda, Bayer, Blueprint Medicines, Chugai, Daiichi Sankyo, EMD Serono, Genentech, Ignyta, KSQ Therapeutics, Loxo, Natera, Novartis, Pfizer, Roche, Taiho, and TP Therapeutics, and honoraria from Foundation Medicine, Guardant, Novartis, Pfizer, and Roche. AN has received fees for consult\/advisory board roles from Boehringer Ingelheim, Roche, Pfizer, Bristol-Myers Squibb, Oryzon Genomics and travel expenses from Pfizer and Boehringer Ingelheim. MLJ has nothing to disclose. JFG has received fees for consulting\/advisory board roles from Bristol-Myers Squibb, Genentech\/Roche, Novartis, Loxo, Theravance, Clovis, Merck, Boehringer Ingelheim, and Incyte. HT, GP, YKP, and AA own stock in and are employees of Pfizer. EF has received fees for consulting\/advisory board roles for Celgene, Eli Lilly, Guardant Health, and Takeda, and has served as a consultant and on the speakers\u2019 bureau for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}